2022
Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance
Hlady RA, Zhao X, Khoury L, Luna A, Pham K, Wu Q, Lee J, Pyrsopoulos NT, Liu C, Robertson KD. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology 2022, 75: 983-996. PMID: 34387871, PMCID: PMC9416882, DOI: 10.1002/hep.32111.Peer-Reviewed Original ResearchConceptsDNA methylationHistone modificationsWide DNA methylationAberrant DNA methylationGene expression analysisDNA methyltransferase inhibitorOpen chromatinEpigenetic mechanismsEpigenetic targetsHuman patient samplesEpigenetic changesEpigenomeMethyltransferase inhibitorTargetable vulnerabilitiesMethylationHCC cell linesImmortalized hepatocytesCell linesFunctional effectsChronic HCV infectionChromatinHCV infectionImmune responsePatient samplesSynergizes
2019
Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination
Wu Q, Wang X, Pham K, Luna A, Studzinski GP, Liu C. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination. The Journal Of Steroid Biochemistry And Molecular Biology 2019, 197: 105524. PMID: 31704246, PMCID: PMC7015782, DOI: 10.1016/j.jsbmb.2019.105524.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaVitamin DOral multi-kinase inhibitorTreatment of HCCAutophagy markers Beclin1Vitamin D insufficiencyCarnosic acidAdvanced hepatocellular carcinomaPromising therapeutic optionVitamin D analogsMulti-kinase inhibitorCell linesElevated protein levelsAnti-oxidant propertiesHCC cell linesHuman neoplastic cellsD insufficiencyGlobal cancer mortalityHepatocellular carcinoma cellsSystemic treatmentTherapeutic optionsCancer mortalityHCC cell deathPreclinical studiesLiver cancerIntegrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma
Hlady RA, Sathyanarayan A, Thompson JJ, Zhou D, Wu Q, Pham K, Lee J, Liu C, Robertson KD. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma. Hepatology 2019, 69: 639-652. PMID: 30136421, PMCID: PMC6351162, DOI: 10.1002/hep.30211.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularCase-Control StudiesDNA MethylationEpigenomeHistone CodeHumansLiverLiver CirrhosisLiver NeoplasmsConceptsHistone modification profilesPromoter/enhancer functionGenome-wide assessmentTranscription of genesEpigenetic marksHistone modificationsEpigenome deregulationEpigenetic regulatorsBioinformatics strategyEpigenetic mechanismsModification profilesEpigenetic underpinningsLiver epigenomeEpigenetic profilesEnhancer functionEpigenetic parametersEpigenomeDecrease cell viabilityDriver lociSignificant deregulationCancer initiationTranscriptionHuman cancersCancer cell linesCell lines
2017
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy 2017, 25: 2299-2308. PMID: 28865999, PMCID: PMC5628867, DOI: 10.1016/j.ymthe.2017.08.005.Peer-Reviewed Original ResearchConceptsC57/B6 miceHepatocellular carcinomaGlypican-3B6 miceIntravenous infusionImmune responseTumor-specific cytotoxic T lymphocyte responsesCytotoxic T lymphocyte responsesBALB/c miceTumor necrosis factor alphaFirst preclinical evidenceLocal immune responseT lymphocyte responsesLimited treatment optionsDurable tumor regressionNecrosis factor alphaAnti-HCC effectsCultured HCC cellsCTL responsesLymphocyte responsesPreclinical evidenceAntibody therapyMost HCC tissuesHigh morbidityTreatment options